Literature DB >> 10908270

Secondary prevention of hypercholesterolaemia: results of an audit conducted in South Wales.

L S Cozma1, A Ogunko, A Rees.   

Abstract

OBJECTIVE: To audit the standards of secondary prevention of coronary heart disease in postmyocardial infarction patients.
DESIGN: Follow up audit, one year after acute admission with myocardial infarction.
SETTING: University Hospital.
SUBJECTS: For the initial admission, 153 patients were audited, with 84 patients contacted one year later. Demographic data, treatment status, and cholesterol levels were analysed both on admission and at follow up.
INTERVENTIONS: Total cholesterol was checked at the audit time either in the hospital or in the doctor's surgery. MAIN OUTCOME MEASURES: Statin doses and cholesterol levels.
RESULTS: Ninety six per cent of patients had their lipid profile performed on admission. Eighty three per cent of the patients with total cholesterol >/= 5 mmol/l were discharged from the hospital on lipid lowering medication. Forty five per cent of the subjects who were followed up had cholesterol levels >/= 5 mmol/l at 1 year. There was a disproportionate use of low doses of statins (lower than those shown in effective trials: simvastatin 20 to 40 mg, pravastatin 40 mg) with a third of all patients on medication not achieving the targets at one year.
CONCLUSION: There was a major improvement in the proportion of patients started on treatment compared with figures reported by previous studies. However, the titration of the statin doses to achieve the targets is still unsatisfactory.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908270      PMCID: PMC1760892          DOI: 10.1136/heart.84.2.e3

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  5 in total

1.  Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

Authors:  M Johannesson; B Jönsson; J Kjekshus; A G Olsson; T R Pedersen; H Wedel
Journal:  N Engl J Med       Date:  1997-01-30       Impact factor: 91.245

2.  Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.

Authors:  T Ashraf; J W Hay; B Pitt; E Wittels; J Crouse; M Davidson; C D Furberg; L Radican
Journal:  Am J Cardiol       Date:  1996-08-15       Impact factor: 2.778

3.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

Authors:  T J Bowker; T C Clayton; J Ingham; N R McLennan; H L Hobson; S D Pyke; B Schofield; D A Wood
Journal:  Heart       Date:  1996-04       Impact factor: 5.994

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

5.  Inadequate management of hyperlipidaemia after coronary bypass surgery shown by medical audit.

Authors:  D B Northridge; A Shandall; A Rees; M B Buchalter
Journal:  Br Heart J       Date:  1994-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.